MedTrace Logo

Study of Low Dose Nesiritide With or Without Sildenafil in Congestive Heart Failure Patients With Renal Dysfunction

NCT00818701 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2010-09-24

No results posted yet for this study

Summary

The purpose of the study is to show that low dose recombinant BNP coupled with phosphodiesterase V inhibition will improve renal dysfunction and promote relief of volume overload in patinets with acute decompensated heart failure complicated by the cardiorenal syndrome.

Conditions

  • Congestive Heart Failure
  • Renal Dysfunction

Interventions

DRUG

low dose Nesiritide

Nesiritide infusion 0.005ug/kg/min

DRUG

nesiritide, Sildenafil

Nesiritide 0.005ug/kg/min Sildenafil 50 mg

Sponsors & Collaborators

Principal Investigators

  • Horng H Chen, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00818701 on ClinicalTrials.gov